C12N 2750/00
Ssdna viruses
Official title: ssDNA viruses
C12N2750/00 (Ssdna viruses) appears on 3,424 US grants and 8,031 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,424
- Published applications
- 8,031
- Assignees
- 1,828
- Inventors
- 10,601
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 4 | 0 |
| 1993 | 4 | 0 |
| 1994 | 5 | 0 |
| 1995 | 6 | 0 |
| 1996 | 14 | 0 |
| 1997 | 18 | 0 |
| 1998 | 40 | 0 |
| 1999 | 40 | 0 |
| 2000 | 34 | 0 |
| 2001 | 51 | 15 |
| 2002 | 46 | 89 |
| 2003 | 39 | 97 |
| 2004 | 26 | 96 |
| 2005 | 28 | 86 |
| 2006 | 45 | 80 |
| 2007 | 46 | 73 |
| 2008 | 28 | 90 |
| 2009 | 35 | 90 |
| 2010 | 57 | 99 |
| 2011 | 36 | 89 |
| 2012 | 38 | 78 |
| 2013 | 44 | 112 |
| 2014 | 55 | 144 |
| 2015 | 77 | 164 |
| 2016 | 87 | 228 |
| 2017 | 126 | 244 |
| 2018 | 146 | 314 |
| 2019 | 157 | 432 |
| 2020 | 199 | 519 |
| 2021 | 256 | 663 |
| 2022 | 245 | 776 |
| 2023 | 290 | 799 |
| 2024 | 303 | 923 |
| 2025 | 418 | 1003 |
| 2026 | 366 | 728 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Capsids and methods of targeting neurons8 Oct 2026US 2026/0306661 A1Capsigen Inc.
- Molecular-genetic strategy for the reactivation of juvenile plasticity in targeted adult neural circuits8 Oct 2026US 2026/0306662 A1The Regents of the University of California
- Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment8 Oct 2026US 2026/0306667 A1Abeona Therapeutics Inc.
- Methods of treating neurodegenerative disorders8 Oct 2026US 2026/0306669 A1
Most cited
By later US patents
- Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants660US 5,750,373 AGenentech, Inc. · 1998
- AAV transduction vectors618US 5,139,941 AUniversity of Florida Research Foundation, Inc. · 1992
- Monovalent phage display562US 5,821,047 AGenentech, Inc. · 1998
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014